University Health Network

Yunhui Lang

Heinz W Pauls

Peter Brent Sampson

Radoslaw Laufer

Yong Liu

Sze-Wan Li

Narendra Kumar B Patel

Grace Ng

Miklos Feher

Bryan T Forrest

Louise G Edwards

Guohua Pan

Yi Yao

Donald E Awrey

Narendra Kumar Patel

Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X; X, and Xis S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I). 

HPK1 inhibitors and methods of using same

The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof. 

Pyrazolopyrimidine compounds

The present teachings provide a compound represented by structural formula (I-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof. 

The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells. 

Indazole compounds as kinase inhibitors and method of treating cancer with same

A CPT1 inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. 

Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer

Growing community of inventors

Markham, Canada

Yunhui Lang